SMS Pharmaceuticals Ltd. Share Price

SMS Pharmaceuticals shows strong profit growth

SMS Pharmaceuticals Limited

reported a sharp improvement in Q1 FY27 profitability, but the revenue growth story remains more moderate. The stock was around ₹471 on October 1, close to its recent highs. What happened Q1 FY27 revenue increased 5.6% year on year to ₹206.96 crore. Operating profit rose 4.5% to ₹30.96 crore, while profit after tax increased 2.0% to ₹20.91 crore. Operating margin was 14.96%. **Why the next quarter matters** The more interesting signal is the September quarter. The available quarterly data shows revenue at ₹242.43 crore, up 23.2% year on year, while operating income rose 67.9% year on year to ₹38.34 crore. Net profit increased 79.5% to ₹25.31 crore. That is a much stronger sequential picture than Q1 and suggests operating leverage may be improving. **My view** I would not judge SMS Pharma only on the Q1 number. The improvement visible in the September-quarter data is more encouraging. However, the stock has already moved close to its recent high, so the next question is whether higher revenue can sustain margins and cash generation. **What I am watching** Revenue growth, operating margin, export performance and whether the September-quarter profitability improvement continues into the second half of FY27. **Stance:** Positive on the earnings trend, but I would wait for confirmation that the margin improvement is sustainable. Disclosure: I do not hold a position in SMS Pharmaceuticals Limited. Not investment advice.

See More

SMS PHARMACEUTICALS LTD — SMSPHARMA | BSE: 532815

Strengths Strong FY26 growth: Revenue from operations increased 13.3% YoY to ₹886.9 Cr in FY26. Improving profitability: FY26 PAT rose about 48% to ₹102 Cr, while EBITDA increased around 23%, with EBITDA margin reaching about 20%. API-focused business: The company has capabilities in APIs and niche molecules, including large-volume molecules and Triptans. 🟠 Weaknesses API business concentration: Dependence on pharmaceutical API demand and pricing can create earnings volatility. Regulatory dependence: A significant part of the business requires continued compliance with USFDA and other international regulatory standards. Capex requirement: Capacity expansion and R&D investment require continuous capital allocation. Product/customer concentration risk: Performance can be affected if key molecules, customers or geographies experience pricing pressure or demand weakness. 🔵 Opportunities Capacity expansion: The company has been pursuing additional capacity and backward-integration projects. R&D expansion: Increased R&D investment can support development of higher-value APIs and new products. Export opportunity: Regulatory approvals can provide access to additional international markets. Specialty/niche APIs: Focus on niche molecules can potentially provide better margins than commoditised APIs. 🔴 Threats USFDA/regulatory risk: Future observations, warning letters or compliance issues could affect exports and manufacturing. API price erosion: Competition from Indian and Chinese manufacturers can pressure selling prices and margins. Raw-material volatility: Changes in input costs can affect profitability. Currency risk: A meaningful export business exposes the company to foreign-exchange movements. Pharma competition: Increasing competition in generic APIs can reduce pricing power.

See More

💊 Business Strength

📊 Recent Price Action Stock recently showed: Sharp single-day rallies (~5–7%) Outperformance vs broader pharma sector in short bursts 👉 Suggests trader interest + momentum-driven moves 💊 Business Strength Core business: Active Pharmaceutical Ingredients (API) Supplies to: Global pharma companies Strong presence in: Anti-ulcer Anti-viral Anti-diabetic segments 🇺🇸 Regulatory & Compliance Earlier: Successful USFDA inspection with no major observations Positive for: Export growth Global credibility ⚖️ Tax Notice (Recent Negative Trigger) Received income tax demand (~₹7 crore) Company stated: No major financial impact expected Reviewing legal options 📅 Upcoming Trigger Q4 & FY26 results expected Trading window closed ahead of results Market waiting for: Continuation of strong growth Margin stability ⚠️ Key Concerns Stock already ran up sharply → risk of consolidation Earnings growth good, but not “high-growth pharma” level Margin volatility possible due to: Raw material costs

See More

Outperformers in a Weak Market: High Relative Strength Stocks 🚀 - PARKHOSPS - BLISSGVS - PFOCUS - INDSWFTLAB - ACUTAAS - ATLANTAELE - AEROFLEX - TORNTPHARM - POWERINDIA - GRANULES - SMSPHARMA - MCX - PRIVISCL - CENTUM

See More

SMS PHARMA — Diversified API Manufacturer Strengthening Its Global Footprint

SMS Pharmaceuticals Ltd is a Hyderabad-based pharmaceutical company focused on manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates across therapeutic areas including anti-ulcer, anti-infective, cardiology, neurology and lifestyle segments. The company operates USFDA-approved and WHO-certified facilities, supplying to leading global formulators. SMS Pharma emphasizes quality compliance, process innovation and cost-efficient production. With a strong export presence, capacity enhancements and a solid regulatory track record, the company aims to scale its specialty and high-value API portfolio while expanding into regulated markets for sustained growth. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link

See More